A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
This company webcast features NeurAxis, Inc. (NYSE American: NRXS). NeurAxis is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. This company webcast was recorded during the Lytham...
This company webcast features Quipt Home Medical (Nasdaq: QIPT / TSX: QIPT). Quipt provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. This company webcast was...
This company webcast features PolyPid Ltd. (Nasdaq: PYPD). PolyPid is a late-stage biopharma company aiming to improve surgical outcomes. This company webcast was recorded during the Lytham Partners 2025 Investor Healthcare Summit.
This company webcast features Reviva Pharmaceuticals Holdings (Nasdaq: RVPH). Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens...
This company webcast features ChromaDex Corp. (Nasdaq: CDXC). ChromaDex is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. This company webcast was recorded during the Lytham Partners 2025 Investor...
This company webcast features Cybin, Inc. (NYSE American: CYBN). Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet...
This company webcast features Beyond Air (Nasdaq: XAIR). Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from...
This company webcast features Kairos Pharma (NYSE American: KAPA). Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. This company webcast was recorded during the...
This company webcast features Genvara BioPharma. Genvara Biopharma's mission is to develop pharmacogenetically-targeted cardiovascular drugs acting through novel mechanisms of action. This company webcast was recorded during the Lytham Partners 2025 Investor...
This company webcast features Botanix Pharmaceuticals (ASX: BOT). Botanix engages in the research and development of dermatology and antimicrobial products in Australia and the United States. This company webcast was recorded during the Lytham Partners 2025 Investor...
During this fireside chat we welcome Osteogene. Osteogene Tech Corp. is dedicated to bettering the health and quality of life for people around the world with our work in the bone graft industry. This fireside chat was recorded during the Lytham Partners 2025 Investor...
During this fireside chat we welcome Unicycive Therapeutics (Nasdaq: UNCY). Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. This fireside chat was recorded during the Lytham Partners 2025 Investor Healthcare Summit.
SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, today announced the...
CARMEL, Ind., Jan. 13, 2025 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that CEO...
Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 millionReports preliminary full-year 2024 revenue in the range of approximately $73.1 million to $73.3 millionIradimed is scheduled to present at the 43rd Annual J.P....
PORTLAND, Maine, Jan. 09, 2025 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), today announced that Chairman and Chief Executive Officer, Quang X. Pham, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on...
Revenues in 4Q24 increased approximately 50% versus 4Q23Cash balance as of 12/31/24 was approximately $3.7 million CARMEL, Ind., Jan. 08, 2025 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing...
JUPITER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and...
DENVER, CO / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that CEO, Josh Disbrow, will participate in a webcasted fireside chat at the Lytham...
CARMEL, Ind., Jan. 06, 2025 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that CEO...
PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla. and MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA")...
PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) today recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin as a superior and safer chronic anticoagulant therapy for warfarin-dependent patients...
WINTER SPRINGS, Fla., Dec. 19, 2024 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging ("MRI") compatible medical devices and the only provider of a non-magnetic intravenous ("IV") infusion pump system...
Lays out Phase 3 Clinical and Regulatory Path for Tecarfarin and Three-Year Strategic Plan PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan...
RED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and manual sensation testing devices without needing electronics or software. NeurAxis Inc. will begin the process of commercially marketing RED and expects initial...
WINTER SPRINGS, Fla., Dec. 10, 2024 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD), today announced it has been ranked 24th on Forbes' list of America's Most Successful Small-Cap Companies 2025. Iradimed is a leader in the development of innovative magnetic...
JERUSALEM, Dec. 04, 2024 -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), an AI-based orthodontic platform company that has developed a proprietary solution to correct people's smiles by straightening teeth using pulsating air delivered by a...
DENVER, CO / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIES, AND SETTLEMENT HEARING IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LITIGATION STYLED WITMER V. ARMISTICE CAPITAL...
WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced it will be presenting at The...
DENVER, CO / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it ranked 380th on the Deloitte Technology Fast 500™, a ranking of the 500...
Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been...
JERUSALEM, Nov. 19, 2024 -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), an AI-based orthodontic platform company, has developed ZSmile, an innovative solution that corrects smiles by straightening teeth, using pulsating air delivered through a...
Recognized as innovative biopharma developing a potentially safer and superior anticoagulant for patients with implanted cardiac devices and rare cardiovascular conditions PONTE VEDRA, Fla., Nov. 19, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a...
Second single-use program to move into production this year highlights new growth opportunity for Precision OpticsGARDNER, Mass., Nov. 14, 2024 -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced...
Conference Call Scheduled for today, November 14, 2024, at 5:00pm ET.GARDNER, Mass., Nov. 14, 2024 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace...
Net income of $1.5 millionAdjusted EBITDA1 of $1.9 millionADHD Portfolio net revenue up 1% to $15.3 millionPediatric Portfolio net revenue up 54% sequentially$20.1 million cash balance at September 30, 2024Organizational changes and operating optimization plan...
PORTLAND, Maine, Nov. 13, 2024 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license...
Leading heart failure specialist features tecarfarin data and Cadrenal's proposed clinical trial protocol at 8th EACTS Mechanical Circulatory Support Summit PONTE VEDRA, Fla., Nov. 12, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage...
Conference call will be held today, Tuesday, November 12 at 9:00 am ETCARMEL, Ind., Nov. 12, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and...
GARDNER, Mass., Nov. 11, 2024 -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference...
PONTE VEDRA, Fla., Nov. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and superior...
Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ETPORTLAND, Maine, Nov. 07, 2024 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven...
DENVER, CO / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the...
CARMEL, Ind., Nov. 05, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized...
JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and...
Clearance expands indication for use from 11-18 year olds to 8-21 year olds; and from 3 devices, not to exceed 4 weeks, to 1 device per week for 4 weeksCARMEL, Ind., Nov. 04, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical...
WINTER SPRINGS, Fla., Nov. 04, 2024 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) was recently named one of Fortune's 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging ("MRI") medical...
PONTE VEDRA, Fla., Nov. 1, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical...